AbbVie Inc (NYSE:ABBV) – Equities research analysts at William Blair upped their Q1 2018 EPS estimates for AbbVie in a research report issued on Monday. William Blair analyst Y. Xu now expects that the company will post earnings per share of $1.80 for the quarter, up from their previous forecast of $1.50. William Blair also issued estimates for AbbVie’s Q3 2018 earnings at $1.95 EPS, Q4 2018 earnings at $2.08 EPS and FY2019 earnings at $8.42 EPS.

A number of other brokerages also recently weighed in on ABBV. Piper Jaffray Companies upped their price target on shares of AbbVie from $115.00 to $130.00 and gave the company an “outperform” rating in a report on Friday, January 26th. Leerink Swann downgraded shares of AbbVie from an “outperform” rating to a “market perform” rating and set a $127.00 price target for the company. in a report on Monday. SunTrust Banks upped their price target on shares of AbbVie to $157.00 and gave the company an “average” rating in a report on Monday. BMO Capital Markets downgraded shares of AbbVie from a “market perform” rating to an “underperform” rating and cut their price target for the company from $125.86 to $84.00 in a report on Monday. They noted that the move was a valuation call. Finally, Evercore ISI reissued a “buy” rating and issued a $144.00 price target on shares of AbbVie in a report on Monday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $115.07.

Shares of AbbVie (NYSE ABBV) traded down $0.01 during midday trading on Wednesday, reaching $116.33. 524,404 shares of the company’s stock were exchanged, compared to its average volume of 6,668,054. AbbVie has a 52 week low of $60.05 and a 52 week high of $125.86. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08. The firm has a market cap of $185,460.00, a P/E ratio of 28.22, a price-to-earnings-growth ratio of 1.07 and a beta of 1.61.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, January 26th. The company reported $1.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.44 by $0.04. AbbVie had a net margin of 18.82% and a return on equity of 152.78%. The company had revenue of $7.74 billion during the quarter, compared to the consensus estimate of $7.53 billion. During the same period in the prior year, the company earned $1.20 EPS. AbbVie’s revenue was up 13.9% on a year-over-year basis.

In other news, SVP Timothy J. Richmond sold 87,040 shares of the stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $98.45, for a total value of $8,569,088.00. Following the completion of the sale, the senior vice president now directly owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total transaction of $20,512,323.93. Following the completion of the sale, the chairman now directly owns 492,030 shares of the company’s stock, valued at $46,255,740.30. The disclosure for this sale can be found here. Insiders have sold 476,376 shares of company stock valued at $45,580,873 over the last ninety days. Insiders own 0.23% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Savant Capital LLC increased its holdings in AbbVie by 1.3% in the second quarter. Savant Capital LLC now owns 61,132 shares of the company’s stock worth $4,433,000 after buying an additional 793 shares during the last quarter. Princeton Capital Management Inc. acquired a new position in AbbVie in the second quarter worth approximately $1,394,000. Palisade Asset Management LLC increased its holdings in AbbVie by 17.9% in the second quarter. Palisade Asset Management LLC now owns 68,311 shares of the company’s stock worth $4,953,000 after buying an additional 10,381 shares during the last quarter. Beaton Management Co. Inc. acquired a new position in AbbVie in the second quarter worth approximately $528,000. Finally, Greatmark Investment Partners Inc. increased its holdings in AbbVie by 3.7% in the second quarter. Greatmark Investment Partners Inc. now owns 35,178 shares of the company’s stock worth $2,551,000 after buying an additional 1,242 shares during the last quarter. 69.28% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “William Blair Weighs in on AbbVie Inc’s Q1 2018 Earnings (ABBV)” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://theolympiareport.com/2018/02/02/william-blair-weighs-in-on-abbvie-incs-q1-2018-earnings-abbv.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Earnings History and Estimates for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.